Zalicus Inc.

Zalicus Inc. (NASDAQ: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators. To learn more about Zalicus, please visit www.zalicus.com.

Rodman & Renshaw Annual Global Investment Conference NYC
Sep 13, 2010 - Sep 15, 2010

Press Kit Files

Title	Type
CombinatoRx changes name to Zalicus Inc. Ticker symbol to ZLCS
Zalicus Corporate Presentation Sept. 2010
Zalicus Fact Sheet.Sept 2010

Disclaimer

Information contained in the Online Press Kit is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.

Requests to copy, circulate or further distribute Online Press Kit documents or content (other than copying for the limited purpose of an individual user's reference) should be submitted to the contact person identified in the Online Press Kit.

Any other requests to copy, circulate or further distribute Online Press Kit documents or content should be made by calling the Business Wire Research Department at +1 800.227.0845.